Differences

This shows you the differences between two versions of the page.

--- philippe_de_wals [2022/04/21 08:49]
liam [Philippe De Wals]
+++ philippe_de_wals [2022/04/21 10:10] (current)
liam [Research]
@@ Line 12: / Line 12: @@
 ===== Career and Affiliations =====
-De Wals is a medical advisor to the [[Institut national de santé publique du Québec]].
+De Wals is a medical advisor to the [[Institut national de santé publique du Québec]]. He is a working group member for [[Vaccines Together]].((//Philippe De Wals.// Vaccines Together. Retrieved April 21, 2022, from https://www.vaccinestogether.org/philippe_de_wals))
 ==== EUROCAT ====
@@ Line 36: / Line 36: @@
 In 2011, he was appointed as Scientific Director of the Evaluation Platform on Obesity Prevention at the [[Quebec Heart and Lung Institute]].
 ==== Public Health Agency of Canada ====
 De Wals is a member of the [[National Advisory Committee on Immunization]] (NACI), where he participated in the approval of [[COVID-19 vaccines]] in Canada.((//National Advisory Committee on Immunization (NACI): Membership and representation. //(2020, December 18). Wayback Machine; Government of Canada. https://web.archive.org/web/20201218222110/https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/naci-membership-representation.html))
+===== Research =====
+De Wals has received research grants and travel reimbursement from [[pharmaceutical_companies:GlaxoSmithKline]], [[pharmaceutical_companies:Merck]], [[pharmaceutical_companies:Novartis]], [[pharmaceutical_companies:Pfizer]], and [[pharmaceutical_companies:Sanofi]]. Specifically, he benefited from unrestricted research grants from GlaxoSmithKline, Pfizer, and Sanofi, for whom he has also served as scientific advisor.((De Wals, P. (2019). //Epidemiology and Control of Meningococcal Disease in Canada: A Long, Complex, and Unfinished Story.// Canadian Journal of Infectious Diseases and Medical Microbiology, 2019, 1–11. https://doi.org/10.1155/2019/8901847)) ((De Wals, P. (2015, October 10). //Economic Analysis of Pneumococcal Vaccination for Elderly Adults in Quebec: Forecasting Invasive Pneumococcal Disease (IPD) Rates of and Serotype Distribution.// Confex; Infectious Diseases Society of America. https://archive.ph/gxSeC))
+Additional funding has come from the [[Public Health Agency of Canada]] and the [[Quebec Ministry of Health and Social Services]].((Cléophat, J.-E., Le Meur, J.-B., Proulx, J.-F., & De Wals, P. (2014). //Uptake of pneumococcal vaccines in the Nordic region of Nunavik, province of Quebec, Canada.// Canadian Journal of Public Health, 105(4), e268–e272. https://doi.org/10.17269/cjph.105.4315))
+In 2021, De Wals participated in the The Pneumococcal Serotype Replacement and Distribution Estimation ([[PSERENADE]]) Project, funded by the [[Bill & Melinda Gates Foundation]] as part of the [[World Health Organization]] [[Pneumococcal Vaccines Technical Coordination Project]].((Deloria Knoll, M., Bennett, J., Garcia Quesada, M., Kagucia, E., Peterson, M., Feikin, D., Cohen, A., Hetrich, M., Yang, Y., Sinkevitch, J., Ampofo, K., Aukes, L., Bacci, S., Bigogo, G., Brandileone, M.-C., Bruce, M., Camilli, R., Castilla, J., Chan, G., & Chanto Chacón, G. (2021). //Global Landscape Review of Serotype-Specific Invasive Pneumococcal Disease Surveillance among Countries Using PCV10/13: The Pneumococcal Serotype Replacement and Distribution Estimation (PSERENADE) Project.// Microorganisms, 9(4), 742. https://doi.org/10.3390/microorganisms9040742))